Phenelzine Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 15 mg
Reference Brands: Nardil®(US)
Category:
Antipsychotropic Drugs
Phenelzine is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) that works by inhibiting the breakdown of serotonin, norepinephrine, and dopamine, thereby increasing their levels in the brain. It is primarily used to treat major depressive disorder (MDD), especially in patients who have not responded to other treatments. Due to its mechanism, dietary restrictions (e.g., avoiding tyramine-rich foods) and careful monitoring for drug interactions are essential to prevent serious adverse effects such as hypertensive crisis.
Phenelzine Tablets is available in Tablets
and strengths such as 15 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Phenelzine Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Phenelzine Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Phenelzine tablets are FDA-approved in the United States for the treatment of major depressive disorder (MDD), particularly in patients unresponsive to other therapies. As a non-selective, irreversible MAOI, phenelzine requires strict regulatory oversight due to risks such as hypertensive crisis and serotonin syndrome. U.S. regulations mandate Boxed Warnings, patient guides, and GMP-compliant manufacturing. Bioequivalence data is needed for generic versions. In the European Union, phenelzine is either rarely used or available through special access programs, due to safety concerns and dietary restrictions. EU dossiers, if applicable, must include Risk Management Plans (RMPs) and robust pharmacovigilance. For global sourcing, visit Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing